Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2024-10-08 DOI:10.1016/j.ejca.2024.115064

Khaled Elsayad , Emmanuella Guenova , Chalid Assaf , Jan P. Nicolay , Franz Trautinger , Rudolf Stadler , Cora Waldstein , Tom Boterberg , Paul Meijnders , Youlia Kirova , Gabor Dobos , Victor Duque-Santana , Elena Riggenbach , Wael Elsheshtawy , Anne Niezink , Evangelia Papadavid , Julia Scarisbrick , Maarten Vermeer , Karen J. Neelis , Martine Bagot , Dora Correia

{"title":"Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group","authors":"Khaled Elsayad , Emmanuella Guenova , Chalid Assaf , Jan P. Nicolay , Franz Trautinger , Rudolf Stadler , Cora Waldstein , Tom Boterberg , Paul Meijnders , Youlia Kirova , Gabor Dobos , Victor Duque-Santana , Elena Riggenbach , Wael Elsheshtawy , Anne Niezink , Evangelia Papadavid , Julia Scarisbrick , Maarten Vermeer , Karen J. Neelis , Martine Bagot , Dora Correia","doi":"10.1016/j.ejca.2024.115064","DOIUrl":null,"url":null,"abstract":"<div><div>The number of primary cutaneous lymphoma patients receiving low-dose radiotherapy is increasing, though controlled clinical trials defining the standard radiation dose for each specific entity have not yet been completed. Radiation oncologists are left with making highly individualized decisions that would be better enriched by additional clinical evidence. In this expert opinion, we aim to provide a clear recommendation to improve the current practice of radiation oncology. In addition, existing literature has been reviewed to develop recommendations for all types of primary cutaneous lymphoma. A prospective trial is urgently needed to identify the factors influencing patient outcomes following different radiation doses.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":7.6000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S095980492401030X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The number of primary cutaneous lymphoma patients receiving low-dose radiotherapy is increasing, though controlled clinical trials defining the standard radiation dose for each specific entity have not yet been completed. Radiation oncologists are left with making highly individualized decisions that would be better enriched by additional clinical evidence. In this expert opinion, we aim to provide a clear recommendation to improve the current practice of radiation oncology. In addition, existing literature has been reviewed to develop recommendations for all types of primary cutaneous lymphoma. A prospective trial is urgently needed to identify the factors influencing patient outcomes following different radiation doses.

查看原文本刊更多论文

皮肤淋巴瘤的放射治疗：EORTC 皮肤淋巴瘤肿瘤小组的建议

接受低剂量放射治疗的原发性皮肤淋巴瘤患者人数在不断增加，但确定每种特定实体标准放射剂量的对照临床试验尚未完成。放射肿瘤专家只能做出高度个体化的决定，而更多的临床证据将更好地丰富这些决定。在这份专家意见中，我们旨在提供明确的建议，以改善目前的放射肿瘤学实践。此外，我们还回顾了现有文献，为所有类型的原发性皮肤淋巴瘤制定了建议。目前亟需进行前瞻性试验，以确定不同放射剂量对患者预后的影响因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.